期刊文献+

三维全息原子场作用矢量用于四氢-咪唑-苯二氮酮类抗艾滋病药物定量构效关系研究 被引量:4

Quantitative structure-activity relationship study of tetrahydroimidazobenzodiazepinone anti-HIV drug using three-dimensional holographic vector of atomic interaction field
下载PDF
导出
摘要 目的对23个四氢-咪唑-苯二氮酮(TIBO)类抗艾滋病药物分子进行定量构效关系(QSAR)研究。方法采用本实验室新近提出的三维全息原子场作用矢量(3D-HoVAIF)表征TIBO类抗艾滋病药物分子结构。然后运用偏最小二乘回归(partial least square regression,PLS)建立3D-HoVAIF描述符与TIBO类抗艾滋病药物活性之间的QSAR模型。结果用此方法建模的复相关系数(R2cum)、交互校验复相关系数(Q2cum)和模型的标准偏差(SD)分别为R2cum=0.824,Q2cum=0.778与SD=0.56,均优于文献值。结论3D-HoVAIF能较好表征TIBO类抗艾滋病药物分子结构信息,因而能建立具有良好稳定性和预测能力的QSAR模型。 Aim To study the quantitative structure-activity relationship (QSAR) of 23 tetrahydroimidazobenzodiazepinone (TIBO) as anti-HIV drug. Methods A newly developed three-dimensional holographic vector of atomic interaction field (3 D-HoVAIF) was used to describe the chemical structure of anti-HIV drug-23 TIBO, a partial least square regression (PLS) model was built. Results The obtained model with the cumulative multiple correlation coefficient (R^2cum) , cumulative cross-validated (Q^2cum) and standard error of estimation (SD) were R^2cum = 0. 824, Q^2cum = 0. 778 and SD = 0.56, respectively. The model had favorable estimation stability and good prediction capabilities. Conclusion Satisfactory results showed that 3D-HoVAIF with definite physic-chemical meanings and easy structural interpretation for structural characterization could preferably express information related to biological activitv of TIRO.
出处 《药学学报》 CAS CSCD 北大核心 2006年第7期654-658,共5页 Acta Pharmaceutica Sinica
基金 山西省工业攻关项目基金资助项目(2006031204) 重庆市应用基础基金资助项目(01-3-6).
关键词 三维全息原子场作用矢量 定量构效关系 四氢-咪唑-苯二氮(艹卓)酮 抗艾滋病药物 three-dimensional holographic vector of atomic interaction field quantitative structureactivity relationship tetrahydroimidazobenzodiazepinone anti-HIV drug
  • 相关文献

参考文献2

二级参考文献67

  • 1EricksonJW. HIV-1 protease as a target for AIDS therapy [ A ]. Ogden RC, Flexner CW. Protease Inhibitors in AIDS Therapy [ M ]. New York: Marcel Dekker, 2001.1 - 25. 被引量:1
  • 2Wlodawer A, Gustchina A. Structural and biochemical studies of retroviral proteases [ J]. Biochim Biophys Acta,2000,1477(1 -2) :16 -34. 被引量:1
  • 3Erik DC. Antiretroviral Therapy [ M ]. Washington D.C.: HSM Press, 2001. 148 - 150. 被引量:1
  • 4Rodriguez-Barrios F, Gago F. HIV protease inhibition:limited recent progress and advances in understanding current pitfalls [ J ]. Curr Top Med Chem, 2004,4 ( 9 ):991 - 1007. 被引量:1
  • 5Turner SR. HIV protease inhibitors the next generation [ J ]. Curr Med Chem Anti-Infective Agents, 2002,1 (2):141 - 162. 被引量:1
  • 6Bucher HC, Young J, Battegay M. Protease inhibitorssparing simplified maintenance therapy: a need for perspective [ J ]. J Antimicrob Chemother, 2004,54 (2):303 - 305. 被引量:1
  • 7King NM, Prabu-Jeyabalan M, Nalivaika EA. Combating susceptibility to drug resistance: lessons from HIV-1 protease [J]. Chem Biol, 2004,11(10) :1333 - 1338. 被引量:1
  • 8PrejdoVa J, Soucek M, Konvalinka J. Determining and overcoming resistance to HIV protease inhibitors [J].Curr Drug Targets Infect Disorders, 2004,4 ( 2 ): 137-152. 被引量:1
  • 9Piliero PJ. Atazanavir: a novel HIV-1 protease inhibitor [J]. Expert Opin Invest Drugs, 2002, 11 (9): 1295 -1301. 被引量:1
  • 10Becker S, Thornton L. Fosamprenavir: advancing HIV protease inhibitor treatment options [ J ]. Expert Opin Pharmacother, 2004,5 (9): 1995 - 2005. 被引量:1

共引文献30

同被引文献55

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部